Correlation between plasma proBNP, echocardiographic and clinical parameters in patientswith type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-3593
Abstract
Aims.
To assess plasma level of N-terminal precursor for brain natriuretic peptide (proBNP) in patients with type 2 diabetes mellitus (T2DM) and arterial hypertension without overt heart failure ? and further estimation of its correlation with data from echocardiog- raphy and clinical parameters (severity of ischemic heart disease (IHD), age, sex, duration of T2DM and hypertension experience, characteristics of glucose and lipid metabolism, renal function.
Materials and methods.
We examined 94 patients with T2DM and arterial hypertension (aged 40?65 years), determining character- istics of glucose and lipid metabolism and renal function. We also performed six minute walk test, ECG, echocardiography and blood tests for N-terminal proBNP (NT-proBNP) in all study subjects. Acquired data was compared to the group of 30 healthy controls.
Results.
We observed an increase in plasma NT-proBNP in patients with IHD, history of left venctricular (LV) myocardial infarction or clinical signs of heart failure (II NYHA class and higher). Results from patients with T2DM and arterial hypertension but without IHD did not significantly differ from control group. Plasma NT-proBNP levels correlated with left ventricular ejection fraction, left ventricular EDD and ESD, but not with LV diastolic function parameters. Duration of T2DM and arterial hypertension, HbA1c levels,27Сахар ный диабет КардиологияСахарный диабет. 2013;(1):27?32BMI, lipid and uric acid metabolism parameters had no influence on plasma NT-proBNP in diabetic patients.
Conclusion.
According to our study, NT-proBNP was elevated in T2DM patients with IHD (and a history of LV myocardial infarc- tion in particular) or clinical evidence for heart failure beyond II NYHA class, thus indicating unfavorable prognosis for this group of patients and need for correction of therapy with subsequent re-evaluation of plasma NT-proBNP.
To assess plasma level of N-terminal precursor for brain natriuretic peptide (proBNP) in patients with type 2 diabetes mellitus (T2DM) and arterial hypertension without overt heart failure ? and further estimation of its correlation with data from echocardiog- raphy and clinical parameters (severity of ischemic heart disease (IHD), age, sex, duration of T2DM and hypertension experience, characteristics of glucose and lipid metabolism, renal function.
Materials and methods.
We examined 94 patients with T2DM and arterial hypertension (aged 40?65 years), determining character- istics of glucose and lipid metabolism and renal function. We also performed six minute walk test, ECG, echocardiography and blood tests for N-terminal proBNP (NT-proBNP) in all study subjects. Acquired data was compared to the group of 30 healthy controls.
Results.
We observed an increase in plasma NT-proBNP in patients with IHD, history of left venctricular (LV) myocardial infarction or clinical signs of heart failure (II NYHA class and higher). Results from patients with T2DM and arterial hypertension but without IHD did not significantly differ from control group. Plasma NT-proBNP levels correlated with left ventricular ejection fraction, left ventricular EDD and ESD, but not with LV diastolic function parameters. Duration of T2DM and arterial hypertension, HbA1c levels,27Сахар ный диабет КардиологияСахарный диабет. 2013;(1):27?32BMI, lipid and uric acid metabolism parameters had no influence on plasma NT-proBNP in diabetic patients.
Conclusion.
According to our study, NT-proBNP was elevated in T2DM patients with IHD (and a history of LV myocardial infarc- tion in particular) or clinical evidence for heart failure beyond II NYHA class, thus indicating unfavorable prognosis for this group of patients and need for correction of therapy with subsequent re-evaluation of plasma NT-proBNP.
About the Authors
Irina Arkad'evna Bondar'
Novosibirsk State Medical University, Novosibirsk
Daria Vladimirovna Grazhdankina
Novosibirsk State Medical University, Novosibirsk
S V Ivanov
Novosibirsk State Regional Hospital, Novosibirsk
Tatiana Viktorovna Panteleeva
Novosibirsk Tuberculosis Research Institute, Novosibirsk
References
1. Дедов ИИ. Сахарный диабет: развитие технологий в диа- гностике, лечении и профилактике (пленарная лекция). Са- харный диабет. 2010;3: 6–13.
2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974 Jul;34(1):29–34.
3. Мареев ВЮ, Агеев ФТ, Арутюнов ГП, Коротеев АВ, Ревиш- вили АШ. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал сердечная недостаточность. 2010;11(1):3–62.
4. Somaratne JB, Whalley GA, Bagg W, Doughty RN. Early detec- tion and significance of structural cardiovascular abnormalities in patients with type 2 diabetes mellitus. Expert Rev Cardiovasc Ther. 2008 Jan;6(1):109–125.
5. Maurellet JD, Liu PT. B-type natriuretic peptide in the management of heart failure. Hong Kong Med J. 2008 Jun;14(3):216–219.
6. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 Feb 12;350(7):655–663.
7. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005 Apr 6;293(13):1609–1616.
8. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N – terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med. 2009 Sep;26(9):872–879. DOI: 10.1111/j.1464–5491.2009.02788.x.
9. Igarashi M, Jimbu Y, Hirata A, Tominaga M. Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes. Endocr J. 2005 Jun;52(3):353-362.
10. Kragelund C, Gustafsson I, Omland T, Grønning B, Køber L, Faber J, Strande S, Steffensen R, Hildebrandt P. Prognostic value of NH2 – terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care. 2006 Jun;29(6):1411–1413.
11. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004 Aug;27(8):1929–1935.
12. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002 Sep 4;40(5):976–982.
13. Аметов АС, Сокарева ЕВ, Гиляревский СР, Дикова ТЕ. Диастолическая дисфункция левого желудочка у больных сахарным диабетом 2 типа. Сахарный диабет. 2008;(1):40–44.
14. Kim JY, Lee EY, Jee JH, Lee BW, Chung JH, Jeun ES, Min YK, Lee MS, Kim KW, Lee MK. N – terminal pro-brain natriuretic peptide (NT-proBNP) in type 2 diabetes with left ventricular disfunction. Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S238–242.
Review
For citations:
Bondar' I.A., Grazhdankina D.V., Ivanov S.V., Panteleeva T.V. Correlation between plasma proBNP, echocardiographic and clinical parameters in patientswith type 2 diabetes mellitus. Diabetes mellitus. 2013;16(1):27-32. (In Russ.) https://doi.org/10.14341/2072-0351-3593
Views:
719
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
